

To shareholders and the press

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

4 May 2016

Exiqon reminds shareholders of deadline for acceptance of the takeover offer from QIAGEN N.V.

A unanimous Board of Directors of Exiqon A/S recommends the company's shareholders to accept the takeover offer from QIAGEN of DKK 18 per share. Exiqon hereby reminds shareholders that the deadline for acceptance of the offer is 18 May 2016.

On Exiqon's webpage www.exiqon.com/investor shareholders can find answers to frequently asked questions, including the following:

Question: *Will my acceptance prevent me from accepting a higher offer from another potential buyer?*

Answer: *No, in that case shareholders are free to accept the higher offer.*

Question: *What happens if QIAGEN does not reach the 90% acceptance threshold and therefore chooses to cancel the takeover offer?*

Answer: *Then Exiqon will face a number of challenges, which were discussed at the recent meetings held with the company's shareholders about the takeover offer. A summary of the meetings is attached and available on Exiqon's webpage.*

Question: *Can I sell my shares for DKK 18 if QIAGEN's offer is cancelled?*

Answer: *No, the share price will then be determined by supply and demand on the stock exchange.*

Additional information

Lars Kongsbak, CEO, Telephone +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, Telephone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon's research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com

